Hunan Dajiaweikang Pharmaceutical IndustryLtd Second Quarter 2024 Earnings: EPS: CN¥0.059 (vs CN¥0.016 in 2Q 2023)

Simply Wall St · 08/30 22:24

Hunan Dajiaweikang Pharmaceutical IndustryLtd (SZSE:301126) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥1.32b (up 48% from 2Q 2023).
  • Net income: CN¥12.4m (up 328% from 2Q 2023).
  • Profit margin: 0.9% (up from 0.3% in 2Q 2023). The increase in margin was driven by higher revenue.
  • EPS: CN¥0.059 (up from CN¥0.016 in 2Q 2023).
earnings-and-revenue-history
SZSE:301126 Earnings and Revenue History August 30th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hunan Dajiaweikang Pharmaceutical IndustryLtd shares are up 5.2% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Hunan Dajiaweikang Pharmaceutical IndustryLtd that you need to take into consideration.